Bayer Sees Increased Demand Across All Consumer Health Categories In Q1
Executive Summary
Bayer Consumer Health reported sales up in all categories and regions in the first quarter of 2022, with demand particularly high for dietary supplements and cough & cold products.
You may also be interested in...
Euro Q2 Consumer Health Earnings Preview: Volatility, Delay, Upturn And Goodbye
Major Europe-based consumer health players Bayer, Sanofi, Reckitt and GSK feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q2 2022 results over the coming weeks.
Bayer And Consumer Health, Like Hand In Glove
“This is an amazing time to be in consumer health. Why would you get rid of an amazing business?” says Heiko Schipper, Bayer's consumer health chief since 2018.
Bayer Beats The Market In 2021 And Has High Hopes For 2022
Bayer Consumer Health posted sales up 6.5% in 2021 as strong demand for supplements and successful launches helped it grow faster than the global market. The company believes it can deliver up to 5% sales growth in 2022 driven by the upcoming launch of Astepro Allergy in the US and the return of the cough & cold category.